G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1864, Issue 7, 2017, Pages 1318-1327

  Rao, Angad ^a   Herr, Deron R ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

Adropin; E cadherin; GPR19; MAPK ERK; Mesenchymal epithelial transition (MET); Orphan GPCR

Indexed keywords

ADROPIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 19; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PEPTIDE HORMONE; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; ENHO PROTEIN, HUMAN; GPR19 PROTEIN, HUMAN; NERVE PROTEIN; NEUROTRANSMITTER RECEPTOR; PEPTIDE; PLASMA PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL INVASION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INTRACELLULAR SIGNALING; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VECTOR CONTROL; CELL ADHESION; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; MAPK SIGNALING; MCF-7 CELL LINE; METABOLISM;

BLOOD PROTEINS; CADHERINS; CELL ADHESION; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; NERVE TISSUE PROTEINS; PEPTIDES; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROTRANSMITTER; UP-REGULATION;

EID: 85019021714     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2017.05.001     Document Type: Article

References (51)

1. [1] Sporn, M.B., The war on cancer. Lancet (London, England) 347 (1996), 1377–1381.
2. [2] Chaffer, C.L., Weinberg, R.A., A perspective on cancer cell metastasis. Science 331 (2011), 1559–1564.
3. [3] Seyfried, T.N., On the origin of cancer metastasis., 18, 2013, 43–73.
4. [4] Thompson, E.W., Newgreen, D.F., Tarin, D., Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition?. Cancer Res. 65 (2005), 5991–5995 (discussion 5995).
5. [5] Lamouille, S., Xu, J., Derynck, R., Molecular mechanisms of epithelial–mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15 (2014), 178–196.
6. [6] Thiery, J.P., Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2 (2002), 442–454.
7. [7] Chao, Y.L., Shepard, C.R., Wells, A., Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol. Cancer 9 (2010), 1–18.
8. [8] Pece, S., Gutkind, J.S., Signaling from E-cadherins to the MAPK pathway by the recruitment and activation of epidermal growth factor receptors upon cell-cell contact formation. J. Biol. Chem. 275 (2000), 41227–41233.
9. [9] Kalluri, R., The basics of epithelial-mesenchymal transition., 119, 2009, 1420–1428.
10. [10] De Craene, B., Berx, G., Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13 (2013), 97–110.
11. [11] Casas, E., Kim, J., Bendesky, A., Ohno-Machado, L., Wolfe, C.J., Yang, J., Snail2 is an essential mediator of Twist1-induced epithelial mesenchymal transition and metastasis. Cancer Res. 71 (2011), 245–254.
12. [12] Larue, L., Bellacosa, A., Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 24 (2005), 7443–7454.
13. [13] Chaffer, C.L., Thompson, E.W., Williams, E.D., Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 185 (2007), 7–19.
14. [14] Chen, J., Han, Q., Pei, D., EMT and MET as paradigms for cell fate switching. J. Mol. Cell Biol. 4 (2012), 66–69.
15. [15] Khalil, B.D., Hsueh, C., Cao, Y., Abi Saab, W.F., Wang, Y., Condeelis, J.S., Bresnick, A.R., Backer, J.M., GPCR signaling mediates tumor metastasis via PI3Kbeta. Cancer Res. 76 (2016), 2944–2953.
16. [16] Herr, D.R., Potential use of G protein-coupled receptor-blocking monoclonal antibodies as therapeutic agents for cancers. Int. Rev. Cell Mol. Biol. 297 (2012), 45–81.
17. [17] Dorsam, R.T., Gutkind, J.S., G-protein-coupled receptors and cancer. Nat. Rev. Cancer 7 (2007), 79–94.
18. [18] Ahmad, R., Wojciech, S., Jockers, R., Hunting for the function of orphan GPCRs – beyond the search for the endogenous ligand. Br. J. Pharmacol. 172 (2015), 3212–3228.
19. [19] Tang, X., Jin, R., Qu, G., Wang, X., Li, Z., Yuan, Z., Zhao, C., Siwko, S., Shi, T., Wang, P., Xiao, J., Liu, M., Luo, J., GPR116, an adhesion G-protein-coupled receptor, promotes breast cancer metastasis via the Galphaq-p63RhoGEF-Rho GTPase pathway. Cancer Res. 73 (2013), 6206–6218.
20. [20] Feigin, M.E., Xue, B., Hammell, M.C., Muthuswamy, S.K., G-protein–coupled receptor GPR161 is overexpressed in breast cancer and is a promoter of cell proliferation and invasion. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 4191–4196.
21. [21] O'Dowd, B.F., Nguyen, T., Lynch, K.R., Kolakowski, L.F., Thompson, M., Cheng, R., Marchese, A., Ng, G., Heng, H.H., George, S.R., A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain. FEBS Lett. 394 (1996), 325–329.
22. [22] Hoffmeister-Ullerich, S.A., Süsens, U., Schaller, H.C., The orphan G-protein-coupled receptor GPR19 is expressed predominantly in neuronal cells during mouse embryogenesis. Cell Tissue Res. 318 (2004), 459–463.
23. [23] Vassilatis, D.K., Hohmann, J.G., Zeng, H., Li, F., Ranchalis, J.E., Mortrud, M.T., Brown, A., Rodriguez, S.S., Weller, J.R., Wright, A.C., Bergmann, J.E., Gaitanaris, G.A., The G protein-coupled receptor repertoires of human and mouse. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 4903–4908.
24. [24] Riker, A.I., Enkemann, S.A., Fodstad, O., Liu, S., Ren, S., Morris, C., Xi, Y., Howell, P., Metge, B., Samant, R.S., Shevde, L.A., Li, W., Eschrich, S., Daud, A., Ju, J., Matta, J., The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med. Genet., 1, 2008, 13.
25. [25] Fève, M., Saliou, J.M., Zeniou, M., Lennon, S., Carapito, C., Dong, J., Van Dorsselaer, A., Junier, M.P., Chneiweiss, H., Cianférani, S., Haiech, J., Kilhoffer, M.C., Comparative expression study of the Endo–G protein coupled receptor (GPCR) repertoire in human Glioblastoma cancer stem-like cells, U87-MG cells and non malignant cells of neural origin unveils new potential therapeutic targets. PLoS One, 9, 2014.
26. [26] Kastner, S., Voss, T., Keuerleber, S., Glockel, C., Freissmuth, M., Sommergruber, W., Expression of G protein-coupled receptor 19 in human lung cancer cells is triggered by entry into S-phase and supports G(2)-M cell-cycle progression. Mol. Cancer Res. 10 (2012), 1343–1358.
27. [27] Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136 (2015), E359–E386.
28. [28] Gunasinghe, N.P., Wells, A., Thompson, E.W., Hugo, H.J., Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 31 (2012), 469–478.
29. [29] Herr, D.R., Lee, C.W., Wang, W., Ware, A., Rivera, R., Chun, J., Sphingosine 1-phosphate receptors are essential mediators of eyelid closure during embryonic development. J. Biol. Chem. 288 (2013), 29882–29889.
30. [30] Harris, G.L., Creason, M.B., Brulte, G.B., Herr, D.R., In vitro and in vivo antagonism of a G protein-coupled receptor (S1P3) with a novel blocking monoclonal antibody. PLoS One, 7, 2012, e35129.
31. [31] Chua, A.W., Hay, H.S., Rajendran, P., Shanmugam, M.K., Li, F., Bist, P., Koay, E.S., Lim, L.H., Kumar, A.P., Sethi, G., Butein downregulates chemokine receptor CXCR4 expression and function through suppression of NF-kappaB activation in breast and pancreatic tumor cells. Biochem. Pharmacol. 80 (2010), 1553–1562.
32. [32] Inoue, A., Ishiguro, J., Kitamura, H., Arima, N., Okutani, M., Shuto, A., Higashiyama, S., Ohwada, T., Arai, H., Makide, K., Aoki, J., TGFalpha shedding assay: an accurate and versatile method for detecting GPCR activation. Nat. Methods 9 (2012), 1021–1029.
33. [33] Herr, D.R., Reolo, M.J.Y., Peh, Y.X., Wang, W., Lee, C.W., Rivera, R., Paterson, I.C., Chun, J., Sphingosine 1-phosphate receptor 2 (S1P(2)) attenuates reactive oxygen species formation and inhibits cell death: implications for otoprotective therapy. Sci. Rep., 6, 2016.
34. [34] Curtis, C., Shah, S.P., Chin, S.F., Turashvili, G., Rueda, O.M., Dunning, M.J., Speed, D., Lynch, A.G., Samarajiwa, S., Yuan, Y., Graf, S., Ha, G., Haffari, G., Bashashati, A., Russell, R., McKinney, S., Langerod, A., Green, A., Provenzano, E., Wishart, G., Pinder, S., Watson, P., Markowetz, F., Murphy, L., Ellis, I., Purushotham, A., Borresen-Dale, A.L., Brenton, J.D., Tavare, S., Caldas, C., Aparicio, S., The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 486 (2012), 346–352.
35. [35] Neve, R.M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F.L., Fevr, T., Clark, L., Bayani, N., Coppe, J.P., Tong, F., Speed, T., Spellman, P.T., DeVries, S., Lapuk, A., Wang, N.J., Kuo, W.L., Stilwell, J.L., Pinkel, D., Albertson, D.G., Waldman, F.M., McCormick, F., Dickson, R.B., Johnson, M.D., Lippman, M., Ethier, S., Gazdar, A., Gray, J.W., A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10 (2006), 515–527.
36. [36] Stein, L.M., Yosten, G.L., Samson, W.K., Adropin acts in brain to inhibit water drinking: potential interaction with the orphan G protein-coupled receptor, GPR19. Am. J. Physiol. Regul. Integr. Comp. Physiol. 310 (2016), R476–R480.
37. [37] Bresnick, J.N., Skynner, H.A., Chapman, K.L., Jack, A.D., Zamiara, E., Negulescu, P., Beaumont, K., Patel, S., McAllister, G., Identification of signal transduction pathways used by orphan g protein-coupled receptors. Assay Drug Dev. Technol. 1 (2003), 239–249.
38. [38] Wong, S.Y., Tan, M.G., Wong, P.T., Herr, D.R., Lai, M.K., Andrographolide induces Nrf2 and heme oxygenase 1 in astrocytes by activating p38 MAPK and ERK. J. Neuroinflammation, 13, 2016, 251.
39. [39] Massihnia, D., Galvano, A., Fanale, D., Perez, A., Castiglia, M., Incorvaia, L., Listi, A., Rizzo, S., Cicero, G., Bazan, V., Castorina, S., Russo, A., Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget, 2016.
40. [40] Furukawa, M., Wheeler, S., Clark, A.M., Wells, A., Lung epithelial cells induce both phenotype alteration and senescence in breast cancer cells. PLoS One, 10, 2015.
41. [41] Chu, K., Boley, K.M., Moraes, R., Barsky, S.H., Robertson, F.M., The paradox of E-Cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism. Oncotarget 4 (2013), 446–462.
42. [42] Butler, A.A., Tam, C.S., Stanhope, K.L., Wolfe, B.M., Ali, M.R., O'Keeffe, M., St-Onge, M.P., Ravussin, E., Havel, P.J., Low circulating Adropin concentrations with obesity and aging correlate with risk factors for metabolic disease and increase after gastric bypass surgery in humans. J. Clin. Endocrinol. Metab. 97 (2012), 3783–3791.
43. [43] Kumar, K.G., Trevaskis, J.L., Lam, D.D., Sutton, G.M., Koza, R.A., Chouljenko, V.N., Kousoulas, K.G., Rogers, P.M., Kesterson, R.A., Thearle, M., Ferrante, A.W. Jr., Mynatt, R.L., Burris, T.P., Dong, J.Z., Halem, H.A., Culler, M.D., Heisler, L.K., Stephens, J.M., Butler, A.A., Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab. 8 (2008), 468–481.
44. [44] Butler, A.A., St-Onge, M.P., Siebert, E.A., Medici, V., Stanhope, K.L., Havel, P.J., Differential responses of plasma Adropin concentrations to dietary glucose or fructose consumption in humans. Sci. Rep., 5, 2015.
45. [45] Gao, S., McMillan, R.P., Zhu, Q., Lopaschuk, G.D., Hulver, M.W., Butler, A.A., Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance. Mol. Metab. 4 (2015), 310–324.
46. [46] Lovren, F., Pan, Y., Quan, A., Singh, K.K., Shukla, P.C., Gupta, M., Al-Omran, M., Teoh, H., Verma, S., Adropin is a novel regulator of endothelial function. Circulation 122 (2010), S185–S192.
47. [47] Hossain, M.S., Mineno, K., Katafuchi, T., Neuronal orphan G-protein coupled receptor proteins mediate plasmalogens-induced activation of ERK and Akt Signaling. PLoS One, 11, 2016, e0150846.
48. [48] Yao, D., Dai, C., Peng, S., Mechanism of the mesenchymal–epithelial transition and its relationship with metastatic tumor formation. Mol. Cancer Res. 9 (2011), 1608–1620.
49. [49] Querzoli, P., Coradini, D., Pedriali, M., Boracchi, P., Ambrogi, F., Raimondi, E., La Sorda, R., Lattanzio, R., Rinaldi, R., Lunardi, M., Frasson, C., Modesti, F., Ferretti, S., Piantelli, M., Iacobelli, S., Biganzoli, E., Nenci, I., Alberti, S., An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. Br. J. Cancer 103 (2010), 1835–1839.
50. [50] Gao, D., Microenvironmental regulation of epithelial-mesenchymal transitions in cancer., 72, 2012, 4883–4889.
51. [51] Gao, D., Joshi, N., Choi, H., Ryu, S., Hahn, M., Catena, R., Sadik, H., Argani, P., Wagner, P., Vahdat, L.T., Port, J.L., Stiles, B., Sukumar, S., Altorki, N.K., Rafii, S., Mittal, V., Myeloid progenitor cells in the premetastatic lung promote metastases by inducing Mesenchymal to epithelial transition. Cancer Res. 72 (2012), 1384–1394.